Upcoming Earnings Overview
Biogen Inc. is set to release its latest quarterly earnings on Tuesday, April 28th, with a consensus estimate EPS of 2.96.
Live Analysis
Biogen Inc. (BIIB) has seen a positive movement today, with the price at $183.6, up by $2.93 (1.62%) from the previous close. The trading volume is at $293,490, reflecting a 23.73% increase relative to the average.
Earnings Overview
The latest quarterly earnings report for Biogen Inc. was on Thursday, February 5th, with a consensus estimate EPS of 1.66. The company's revenue and profit margin figures are expected to be revealed in the upcoming report.
Cash Flow
Biogen Inc. reported a net change in cash of -$856.6 million for the period, with operating cash flow at $512 million. The company ended the period with $3 billion in cash.
Income Statement
In the last period, Biogen Inc. generated revenue of $2.28 billion with a gross profit of $1.78 billion. The company reported a net income of -$48.41 million, resulting in an EPS of -33 cents.
Ratios
Key financial ratios show a quick ratio of 2.03, gross profit margin at 78.23%, and a debt ratio of 23.6%. The price-to-earnings ratio stands at -133.33.
Balance Sheet
Biogen Inc.'s total assets amount to $29.44 billion, with total liabilities at $11.18 billion. The company holds $3 billion in cash and cash equivalents.
This comprehensive financial snapshot provides insights into Biogen Inc.'s current performance and upcoming earnings announcement.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.